Director · Vanda Pharmaceuticals Inc. · Common Stock
Side
BUY
Value
$22K
Shares
5,803
Price
$3.8
Executed
Nov 5, 2026
Disclosed
Nov 5, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 5 executedNov 5, 2026 disclosed
VNDA · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Duncan Charles Cliff filed this Form 4 reporting a open-market purchase of VNDA on Nov 5, 2026. It became public on Nov 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Duncan Charles Cliffcik:0002130896
Issuer
Vanda Pharmaceuticals Inc.cik:0001347178
Revision history · 0
No field has changed since this record was first ingested.
VNDAVanda Pharmaceuticals Inc.